These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31331828)

  • 1. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
    de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
    Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
    Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
    Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis.
    Sousa-Batista AJ; Pacienza-Lima W; Arruda-Costa N; Falcão CAB; Ré MI; Rossi-Bergmann B
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of
    Rebouças-Silva J; Tadini MC; Devequi-Nunes D; Mansur AL; S Silveira-Mattos P; I de Oliveira C; R Formiga F; Berretta AA; Marquele-Oliveira F; Borges VM
    Int J Nanomedicine; 2020; 15():8659-8672. PubMed ID: 33177824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
    Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
    J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Amphotericin B-Conjugated Functionalized Carbon Nanoparticles in the Treatment of Cutaneous Leishmaniasis.
    Heidari-Kharaji M; Guerra SS; Puneiad RP
    Parasite Immunol; 2024 Oct; 46(10):e13068. PubMed ID: 39363635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
    Frankenburg S; Glick D; Klaus S; Barenholz Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
    Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
    J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B.
    Pandya S; Verma RK; Khare P; Tiwari B; Srinivasarao DA; Dube A; Goyal N; Misra A
    Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):125-32. PubMed ID: 27183429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.